Compounding pharmacies and other businesses that have been restricted from the GLP-1 boom may be poised to cash in on a new windfall: the exploding market for peptides. The market for peptides — heavily hyped but loosely regulated substances made of short amino acid chains — could top $295 billion by 2033 if the Trump administration relaxes manufacturing rules. A Food and Drug Administration advisory panel will evaluate whether to loosen restrictions on compounding — the process of creating customized medications — for seven peptides in a two-day meeting starting Thursday.
Read the full article: FDA Peptide Review Could Lead to New Compounding Boom //
Source: https://www.axios.com/2026/07/23/peptides-fda-compounding-review-market-safety